[go: up one dir, main page]

WO2009018367A3 - Nouvelles formes de sels de (2s)-(4e)-n-méthyl-5-[3-(5-méthoxypyridin)yl]-4-pentén-2-amine - Google Patents

Nouvelles formes de sels de (2s)-(4e)-n-méthyl-5-[3-(5-méthoxypyridin)yl]-4-pentén-2-amine Download PDF

Info

Publication number
WO2009018367A3
WO2009018367A3 PCT/US2008/071631 US2008071631W WO2009018367A3 WO 2009018367 A3 WO2009018367 A3 WO 2009018367A3 US 2008071631 W US2008071631 W US 2008071631W WO 2009018367 A3 WO2009018367 A3 WO 2009018367A3
Authority
WO
WIPO (PCT)
Prior art keywords
penten
methoxypyridin
amine
methyl
salt forms
Prior art date
Application number
PCT/US2008/071631
Other languages
English (en)
Other versions
WO2009018367A2 (fr
Inventor
Gary Maurice Dull
Julio A. Munoz
John Genus
Balwinder Singh Bhatti
Jennifer A. Young
Merouane Bencherif
John W. James
Michael G. Williams
Kristen Jordan
Patrick M. Lippiello
Beth Fordham-Meier
Original Assignee
Targacept, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept, Inc. filed Critical Targacept, Inc.
Publication of WO2009018367A2 publication Critical patent/WO2009018367A2/fr
Publication of WO2009018367A3 publication Critical patent/WO2009018367A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des sels de 2S)-(4E)-n-méthyl-5-[3-(5-méthoxypyridin)yl]-4-pentén-2-amine, des procédés pour leur préparation, des compositions pharmaceutiques comprenant lesdits sels, et leur utilisation. Les sels peuvent être administrés à des patients prédisposés à des affections ou des troubles ou souffrant de ceux-ci, tels que des troubles du système nerveux central, pour traiter ou prévenir de tels troubles.
PCT/US2008/071631 2007-07-31 2008-07-30 Nouvelles formes de sels de (2s)-(4e)-n-méthyl-5-[3-(5-méthoxypyridin)yl]-4-pentén-2-amine WO2009018367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95306407P 2007-07-31 2007-07-31
US60/953,064 2007-07-31

Publications (2)

Publication Number Publication Date
WO2009018367A2 WO2009018367A2 (fr) 2009-02-05
WO2009018367A3 true WO2009018367A3 (fr) 2010-05-27

Family

ID=40019374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071631 WO2009018367A2 (fr) 2007-07-31 2008-07-30 Nouvelles formes de sels de (2s)-(4e)-n-méthyl-5-[3-(5-méthoxypyridin)yl]-4-pentén-2-amine

Country Status (1)

Country Link
WO (1) WO2009018367A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045538B2 (en) * 1996-04-23 2006-05-16 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO2006053039A2 (fr) * 2004-11-10 2006-05-18 Targacept, Inc. Sels hydroxybenzoates de composes metanicotine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045538B2 (en) * 1996-04-23 2006-05-16 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO2006053039A2 (fr) * 2004-11-10 2006-05-18 Targacept, Inc. Sels hydroxybenzoates de composes metanicotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STAHL P H ET AL: "Handbook of Pharmaceutical salts, passage", HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, WEINHEIM : WILEY-VCH VERLAG, DE, 1 January 2002 (2002-01-01), pages 329 - 333,342, XP002472779, ISBN: 978-3-906390-26-0 *
WERMUTH C G ET AL: "Handbook of Pharmaceutical Salts passsage", HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, WEINHEIM : WILEY-VCH VERLAG, DE, 1 January 2002 (2002-01-01), pages 1 - 7, XP002421267, ISBN: 978-3-906390-26-0 *

Also Published As

Publication number Publication date
WO2009018367A2 (fr) 2009-02-05

Similar Documents

Publication Publication Date Title
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
WO2010114824A8 (fr) Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2007127505A3 (fr) Composés chimiques
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
WO2012078593A3 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
WO2008094992A3 (fr) Inhibiteurs de kinase
WO2008076392A3 (fr) Composés utilisables en tant qu'inhibiteurs de protéines kinases
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
GEP20146082B (en) Compositions and methods of wnt signaling modulators
WO2011041694A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2012016186A8 (fr) Inhibiteurs de kinases macrocycliques et leurs utilisations
WO2007095188A3 (fr) Dihydrodiazepines servant d'inhibiteurs des proteines kinases
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
WO2008112651A3 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
WO2007120760A3 (fr) Thiophène-carboxamides servant d'inhibiteurs de protéines kinases
WO2007139816A3 (fr) Thiophène-carboxamides pouvant être employés en tant qu'inhibiteurs de protéine kinase
WO2008020306A3 (fr) Dérivés d'isoindole
WO2009038385A3 (fr) Nouveaux composés présentant des squelettes d'indazole, méthodes de préparation de ceux-ci et composition pharmaceutique les contenant
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2007136741A3 (fr) N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
WO2008060597A3 (fr) Composés utiles comme inhibiteurs de protéines kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08782540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08782540

Country of ref document: EP

Kind code of ref document: A2